Vanguard Group Discloses Position in Oxford Biomedica

The Vanguard Group, Inc. has made a public disclosure about its position in Oxford Biomedica plc. According to the filing under Form 8.3, the company's interest represents more than 1% of the relevant securities. On the disclosure date, 11 February 2026, Vanguard reported holding 1,219,024 ordinary shares, equating to a 1.01% interest in Oxford Biomedica's ordinary shares, each valued at 50p.

Additionally, there was a small purchase of 3,890 shares at a price of 8.16 GBP per share. The disclosure clarifies there are no rights to subscribe for new securities and no stock-settled or cash-settled derivative positions pertaining to these securities. Moreover, Vanguard reported no indemnity, option arrangements, or understandings influencing dealings in the relevant securities.

Vanguard’s disclosure is in accordance with Rule 8.3 of the Takeover Code, requiring parties with significant interests to declare their holdings.